185 related articles for article (PubMed ID: 8552075)
1. Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes.
Soddu S; Blandino G; Scardigli R; Martinelli R; Rizzo MG; Crescenzi M; Sacchi A
Mol Cell Biol; 1996 Feb; 16(2):487-95. PubMed ID: 8552075
[TBL] [Abstract][Full Text] [Related]
2. Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells.
Martinelli R; Blandino G; Scardigli R; Crescenzi M; Lombardi D; Sacchi A; Soddu S
Oncogene; 1997 Jul; 15(5):607-11. PubMed ID: 9247315
[TBL] [Abstract][Full Text] [Related]
3. Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras.
Cristofanelli B; Valentinis B; Soddu S; Rizzo MG; Marchetti A; Bossi G; Morena AR; Dews M; Baserga R; Sacchi A
Oncogene; 2000 Jul; 19(29):3245-55. PubMed ID: 10918581
[TBL] [Abstract][Full Text] [Related]
4. Cellular aging is a critical determinant of primary cell resistance to v-src transformation.
Tavoloni N; Inoue H
J Virol; 1997 Jan; 71(1):237-47. PubMed ID: 8985343
[TBL] [Abstract][Full Text] [Related]
5. Expression of transfected recombinant oncogenes increases radiation resistance of clonal hematopoietic and fibroblast cell lines selectively at clinical low dose rate.
FitzGerald TJ; Henault S; Sakakeeny M; Santucci MA; Pierce JH; Anklesaria P; Kase K; Das I; Greenberger JS
Radiat Res; 1990 Apr; 122(1):44-52. PubMed ID: 2320725
[TBL] [Abstract][Full Text] [Related]
6. Growth factor modulation of p53-mediated growth arrest versus apoptosis.
Canman CE; Gilmer TM; Coutts SB; Kastan MB
Genes Dev; 1995 Mar; 9(5):600-11. PubMed ID: 7698649
[TBL] [Abstract][Full Text] [Related]
7. Wild-type p53 modulates apoptosis of normal, IL-3 deprived, hematopoietic cells.
Blandino G; Scardigli R; Rizzo MG; Crescenzi M; Soddu S; Sacchi A
Oncogene; 1995 Feb; 10(4):731-7. PubMed ID: 7862450
[TBL] [Abstract][Full Text] [Related]
8. Distinct regulation of glucose transport by interleukin-3 and oncogenes in a murine bone marrow-derived cell line.
Ahmed N; Berridge MV
Biochem Pharmacol; 1999 Feb; 57(4):387-96. PubMed ID: 9933027
[TBL] [Abstract][Full Text] [Related]
9. Transforming oncogenes regulate glucose transport by increasing transporter affinity for glucose: contrasting effects of oncogenes and heat stress in a murine marrow-derived cell line.
Ahmed N; Berridge MV
Life Sci; 1998; 63(21):1887-903. PubMed ID: 9825767
[TBL] [Abstract][Full Text] [Related]
10. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
Dolnikov A; Millington M; Sun LQ; Symonds G
Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of transforming growth factor-beta 1 (TGF-beta 1) receptors in murine myeloid cell lines transformed with oncogenes. Correlation with differential growth inhibition by TGF-beta 1.
Birchenall-Roberts MC; Falk LA; Kasper J; Keller J; Faltynek CR; Ruscetti FW
J Biol Chem; 1991 May; 266(15):9617-21. PubMed ID: 1851752
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle.
Anderson SM; Carroll PM; Lee FD
Oncogene; 1990 Mar; 5(3):317-25. PubMed ID: 2107491
[TBL] [Abstract][Full Text] [Related]
13. Regulation of glucose transport by interleukin-3 in growth factor-dependent and oncogene-transformed bone marrow-derived cell lines.
Ahmed N; Berridge MV
Leuk Res; 1997 Jul; 21(7):609-18. PubMed ID: 9301681
[TBL] [Abstract][Full Text] [Related]
14. Cooperation of p53 and polyoma virus middle T antigen in the transformation of primary rat embryo fibroblasts.
Reihsaus E; Kraiss S; Barnekow A; Montenarh M
Exp Cell Res; 1992 Mar; 199(1):10-8. PubMed ID: 1735451
[TBL] [Abstract][Full Text] [Related]
15. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability.
Fukasawa K; Vande Woude GF
Mol Cell Biol; 1997 Jan; 17(1):506-18. PubMed ID: 8972231
[TBL] [Abstract][Full Text] [Related]
16. BCR/ABL recruits p53 tumor suppressor protein to induce drug resistance.
Stoklosa T; Slupianek A; Datta M; Nieborowska-Skorska M; Nowicki MO; Koptyra M; Skorski T
Cell Cycle; 2004 Nov; 3(11):1463-72. PubMed ID: 15492510
[TBL] [Abstract][Full Text] [Related]
17. TEL/ETV6 induces apoptosis in 32D cells through p53-dependent pathways.
Yamagata T; Maki K; Waga K; Mitani K
Biochem Biophys Res Commun; 2006 Aug; 347(2):517-26. PubMed ID: 16828711
[TBL] [Abstract][Full Text] [Related]
18. Rescue of K562 cells from MDM2-modulated p53-dependent apoptosis by growth factor-induced differentiation.
Mahdi T; Alcalay D; Cognard C; Tanzer J; Kitzis A
Biol Cell; 1998 Dec; 90(9):615-27. PubMed ID: 10085538
[TBL] [Abstract][Full Text] [Related]
19. Exogenous wt-p53 protein is active in transformed cells but not in their non-transformed counterparts: implications for cancer gene therapy without tumor targeting.
D'Orazi G; Marchetti A; Crescenzi M; Coen S; Sacchi A; Soddu S
J Gene Med; 2000; 2(1):11-21. PubMed ID: 10765501
[TBL] [Abstract][Full Text] [Related]
20. Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
Zhu J; Nabissa PM; Hoffman B; Liebermann DA; Shore SK
Blood; 1996 May; 87(10):4368-75. PubMed ID: 8639797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
